A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab

Mod Rheumatol. 2016 Nov;26(6):813-816. doi: 10.3109/14397595.2016.1168536. Epub 2016 May 5.

Abstract

Objectives: The aim of the present study was to generate a novel method for predicting the clinical response to infliximab (IFX), using a machine-learning algorithm with only clinical data obtained before the treatment in rheumatoid arthritis (RA) patients.

Methods: We obtained 32 variables out of the clinical data on the patients from two independent hospitals. Next, we selected both clinical parameters and machine-learning algorithms and decided the candidates of prediction method. These candidates were verified by clinical variables on different patients from two other hospitals. Finally, we decided the prediction method to achieve the highest score.

Results: The combination of multilayer perceptron algorithm (neural network) and nine clinical parameters shows the best accuracy performance. This method could predict the good or moderate response to IFX with 92% accuracy. The sensitivity of this method was 96.7%, while the specificity was 75%.

Conclusions: We have developed a novel method for predicting the clinical response using only background clinical data in RA patients before treatment with IFX. Our method for predicting the response to IFX in RA patients may have advantages over the other previous methods in several points including easy usability, cost-effectiveness and accuracy.

Keywords: Clinical data; Infliximab; Machine-learning; Rheumatoid arthritis; The prediction of clinical response.

MeSH terms

  • Adult
  • Aged
  • Algorithms
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / drug therapy*
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Infliximab / therapeutic use*
  • Machine Learning
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Symptom Assessment
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Infliximab